Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 ...
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Thursday announced positive data from INSIGHT-003 Phase I trial, evaluating the addition of Eftilagimod alpha or ...
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Jemperli plus chemotherapy demonstrated superior overall survival ... Keytruda group. A first-line treatment combination of ...
Other causes of lung cancer are well known, like radon gas exposure, which happens to be fairly prevalent in Appalachia. It’s ...
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback